| Multiple Myeloma
Carvykti vs Darzalex Faspro
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Carvykti vs Darzalex Faspro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDarzalex Faspro has a higher rate of injection site reactions vs Carvykti based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Darzalex Faspro but not Carvykti, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Carvykti
Darzalex Faspro
At A Glance
IV infusion
Single infusion
BCMA-directed CAR-T cell therapy
SC injection
Weekly, then every 2 weeks, then every 4 weeks
CD38-directed monoclonal antibody
Indications
- Multiple Myeloma
- Multiple Myeloma
- Smoldering myeloma
- Light chain (AL) amyloidosis
Dosing
Multiple Myeloma 0.5-1.0x10^6 CAR-positive viable T cells/kg IV (max 1x10^8 cells) as a single infusion, administered 2-4 days after lymphodepleting chemotherapy (cyclophosphamide 300 mg/m^2 IV and fludarabine 30 mg/m^2 IV daily for 3 days); premedicate with acetaminophen and an H1-antihistamine 30-60 minutes prior to infusion.
Multiple Myeloma 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until disease progression. Dosing schedule varies by combination regimen (with lenalidomide-dexamethasone, bortezomib-melphalan-prednisone, bortezomib-thalidomide-dexamethasone, bortezomib-lenalidomide-dexamethasone, bortezomib-dexamethasone, pomalidomide-dexamethasone, or carfilzomib-dexamethasone) or as monotherapy.
Smoldering myeloma 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until diagnosis of multiple myeloma or maximum 3 years.
Light chain (AL) amyloidosis 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes in combination with bortezomib-cyclophosphamide-dexamethasone. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until disease progression or maximum 2 years.
Contraindications
—
- Severe hypersensitivity to daratumumab, hyaluronidase, or any component of the formulation
Adverse Reactions
Most common (>20%) Pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, vomiting
Serious Pneumonia, cytokine release syndrome, sepsis, encephalopathy, viral infection, cranial nerve palsies
Postmarketing T cell malignancies including T-cell lymphoma, immune effector cell-associated enterocolitis and gastrointestinal perforation, infusion related reactions, JC virus progressive multifocal leukoencephalopathy
Most common (>=20%) Upper respiratory tract infection, fatigue, peripheral neuropathy, musculoskeletal pain, constipation, diarrhea, insomnia, rash, edema, pyrexia, nausea, cough, dyspnea, sensory neuropathy, injection site reactions, infusion reactions, headache, decreased appetite, sleep disorder
Serious Pneumonia, cardiac failure, sepsis, thromboembolism, COVID-19, neutropenia, thrombocytopenia, arrhythmia, cardiac arrest, herpes zoster, hepatitis B reactivation, cytomegalovirus infection, listeriosis, atrial fibrillation, pancreatitis, pulmonary edema, anaphylactic reaction
Pharmacology
CARVYKTI is a BCMA-directed, genetically modified autologous T cell immunotherapy that reprograms a patient's own T cells with a transgene encoding a CAR featuring two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain, and a CD3-zeta signaling domain; upon binding to BCMA-expressing cells, the CAR promotes T cell activation, expansion, and elimination of target cells.
Daratumumab is a CD38-directed IgG1 kappa monoclonal antibody that induces tumor cell death through multiple immune-mediated mechanisms including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and direct apoptosis via Fc-mediated crosslinking.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Carvykti
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Darzalex Faspro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Carvykti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Darzalex Faspro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Carvykti
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Darzalex Faspro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableLeukemia & Lymphoma Society (LLS): Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Amyloidosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CarvyktiView full Carvykti profile
Darzalex FasproView full Darzalex Faspro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.